HAE.NYSEHaemonetics CORP

Form 4: Haemonetics EVP, Chief Financial Officer James D'Arecca Reports Changes in Beneficial Ownership

Sentiment:

SEC Form 4 Filing

📋All filings for Haemonetics CORP
🔒Login to Follow

James D'Arecca, EVP and Chief Financial Officer of Haemonetics Corp, reports a transaction involving the withholding of shares for tax obligations related to vesting restricted stock units.

Summary

  • On May 2, 2024, James D'Arecca, the EVP and Chief Financial Officer of Haemonetics Corp, had shares withheld to cover tax obligations related to the vesting of restricted stock units (RSUs).
  • A total of 432 shares of common stock were disposed of at a price of $93.33 per share to satisfy these tax obligations.
  • Following the transaction, D'Arecca beneficially owns 13,670 shares of Haemonetics Corp, which includes unvested RSUs.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to insider transactions. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and their impact on their holdings. This filing indicates a standard transaction related to executive compensation and tax obligations.

Stakeholder Impact

  • The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations related to executive compensation.

Key Dates

DateDescription
05/02/2024Date of transaction: shares withheld for tax obligations related to vesting of RSUs.
05/06/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.